1. Home
  2. CMND vs CDT Comparison

CMND vs CDT Comparison

Compare CMND & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMND
  • CDT
  • Stock Information
  • Founded
  • CMND 2017
  • CDT 2019
  • Country
  • CMND Canada
  • CDT United States
  • Employees
  • CMND N/A
  • CDT N/A
  • Industry
  • CMND Biotechnology: Pharmaceutical Preparations
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMND Health Care
  • CDT Health Care
  • Exchange
  • CMND Nasdaq
  • CDT Nasdaq
  • Market Cap
  • CMND 5.3M
  • CDT 4.6M
  • IPO Year
  • CMND N/A
  • CDT N/A
  • Fundamental
  • Price
  • CMND $1.03
  • CDT $1.68
  • Analyst Decision
  • CMND
  • CDT
  • Analyst Count
  • CMND 0
  • CDT 0
  • Target Price
  • CMND N/A
  • CDT N/A
  • AVG Volume (30 Days)
  • CMND 67.3K
  • CDT 81.6K
  • Earning Date
  • CMND 09-15-2025
  • CDT 08-14-2025
  • Dividend Yield
  • CMND N/A
  • CDT N/A
  • EPS Growth
  • CMND N/A
  • CDT N/A
  • EPS
  • CMND N/A
  • CDT N/A
  • Revenue
  • CMND N/A
  • CDT N/A
  • Revenue This Year
  • CMND N/A
  • CDT N/A
  • Revenue Next Year
  • CMND N/A
  • CDT N/A
  • P/E Ratio
  • CMND N/A
  • CDT N/A
  • Revenue Growth
  • CMND N/A
  • CDT N/A
  • 52 Week Low
  • CMND $0.80
  • CDT $1.47
  • 52 Week High
  • CMND $2.18
  • CDT $274.80
  • Technical
  • Relative Strength Index (RSI)
  • CMND 54.80
  • CDT 38.23
  • Support Level
  • CMND $0.96
  • CDT $1.47
  • Resistance Level
  • CMND $1.05
  • CDT $1.85
  • Average True Range (ATR)
  • CMND 0.05
  • CDT 0.11
  • MACD
  • CMND -0.00
  • CDT 0.02
  • Stochastic Oscillator
  • CMND 80.00
  • CDT 48.84

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: